A greater rating intended that signs of BPH ended up even worse. The intention was to have a reduce rating, which implies that people have had much less and fewer intense signs and symptoms of BPH.[eight] The FDA concluded they were not able to draw a result in and influence relationship, only an association; the label of all 3 PDE5 inhibitors was